BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsClinical readout

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis

Open original release

Related news

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

AVTXAvalo Therapeutics2026-05-05 20:01 EST

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

CLDXCelldex Therapeutics2026-06-14 09:15 EST

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

BNTXBioNTech2026-05-22 09:00 EST

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

SABSSAB Biotherapeutics2026-04-22 11:00 EST

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

NRIXNurix Therapeutics2026-05-14 20:06 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

KYMRKymera2026-03-28 15:00 EST

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

View all latest news

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a biotechnology company focused on inflammatory skin and immune-mediated diseases. Its story is built around developing differentiated therapies for conditions like hidradenitis suppurativa and other inflammatory disorders.

Recent company news

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-03-28 19:00 EST

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MLTXMoonLake Immunotherapeutics2026-02-22 16:00 EST

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

MLTXMoonLake Immunotherapeutics2026-02-02 13:00 EST

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

MLTXMoonLake Immunotherapeutics2026-01-08 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

Stock data

Close
19.88 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States